Table 1.
Baseline patient characteristics
| All Patients | Pirfenidone | Nintedanib | P Value1 | |
|---|---|---|---|---|
| N = 1455 | N = 799 | N = 656 | ||
| Age, mean (SD) | 70.9 (9.5) | 70.6 (9.4) | 71.3 (9.7) | 0.222 |
| Age categories, years, n (%) | 0.581 | |||
| 40–44 | 1 (0.1) | 1 (0.1) | (0.0) | |
| 45–54 | 68 (4.7) | 36 (4.5) | 32 (4.9) | |
| 55–64 | 377 (25.9) | 212 (26.5) | 165 (25.2) | |
| 65–74 | 445 (30.6) | 255 (31.9) | 190 (29.0) | |
| 75–79 | 269 (18.5) | 140 (17.5) | 129 (19.7) | |
| ≥ 80 | 295 (20.3) | 155 (19.4) | 140 (21.3) | |
| Female, n (%) | 456 (31.3) | 256 (32.0) | 200 (30.5) | 0.525 |
| Region, n (%) | 0.010 | |||
| Northeast | 271 (18.6) | 157 (19.6) | 114 (17.4) | |
| North Central | 457 (31.4) | 236 (29.5) | 221 (33.7) | |
| South | 554 (38.1) | 294 (36.8) | 260 (39.6) | |
| West | 169 (11.6) | 111 (13.9) | 58 (8.8) | |
| Unknown | 4 (0.3) | 1 (0.1) | 3 (0.5) | |
| CCI, mean (SD) | 2.1 (2.0) | 2.1 (2.0) | 2.1 (1.9) | 0.512 |
| excluding COPD, mean (SD) | 1.9 (2.0) | 1.9 (2.0) | 1.9 (1.9) | 0.680 |
| Proxies of disease severity, n (%) | ||||
| Presence of supplemental oxygen use | 868 (59.7) | 478 (59.8) | 390 (59.5) | 0.885 |
| Diagnosis of dyspnea | 1131 (77.7) | 621 (77.7) | 510 (77.7) | 0.992 |
| Prescription for ≥1 opioid(s) | 557 (38.3) | 306 (38.3) | 251 (38.3) | 0.989 |
| Presence of comorbid conditions, n (%) | ||||
| Any cardiovascular disease | 640 (44.0) | 354 (44.3) | 286 (43.6) | 0.787 |
| Stroke | 37 (2.5) | 23 (2.9) | 14 (2.1) | 0.369 |
| COPD | 692 (47.6) | 359 (44.9) | 333 (50.8) | 0.027 |
| Emphysema | 189 (13.0) | 99 (12.4) | 90 (13.7) | 0.453 |
| Bronchitis | 101 (6.9) | 51 (6.4) | 50 (7.6) | 0.355 |
| Chronic bronchitis | 156 (10.7) | 73 (9.1) | 83 (12.7) | 0.031 |
| Chronic airway obstruction | 562 (38.6) | 289 (36.2) | 273 (41.6) | 0.034 |
| Cancer | 269 (18.5) | 154 (19.3) | 115 (17.5) | 0.394 |
| Lung cancer | 31 (2.1) | 21 (2.6) | 10 (1.5) | 0.147 |
| Recent pnemonia2 | 149 (10.2) | 77 (9.6) | 72 (11.0) | 0.402 |
| All-cause total costs, mean (SD) | $31,933 ($54,125) | $31,849 ($44,706) | $32,035 ($63,781) | 0.948 |
| Visit to ILD center of excellence3, n (%) | 110 (7.6) | 57 (7.1) | 53 (8.1) | 0.497 |
CCI Charlson Comorbidity Index, COPD chronic obstructive pulmonary disease, SD standard deviation
1Pirfenidone vs. nintedanib
2Pneumonia diagnosis in the 3 months immediately preceding the index date
3 Patient was treated at an Interstitial Lung Disease (ILD) Center of Excellence as identified by zip code of facility. Centers of excellence were defined as medical centers with specific expertise in the treatment of pulmonary fibrosis, as recognized by the Pulmonary Fibrosis Foundation